Shares of Immunomedics, Inc. (NASDAQ:IMMU) have earned an average rating of “Buy” from the six analysts that are presently covering the stock, MarketBeat Ratings reports. Two analysts have rated the stock with a hold recommendation and four have given a buy recommendation to the company. The average 12 month target price among brokerages that have issued a report on the stock in the last year is $15.50.
A number of equities research analysts have weighed in on IMMU shares. BidaskClub lowered Immunomedics from a “buy” rating to a “hold” rating in a report on Friday, August 4th. Zacks Investment Research lowered Immunomedics from a “buy” rating to a “hold” rating in a report on Thursday, August 10th. Finally, Jefferies Group LLC set a $11.00 price objective on Immunomedics and gave the company a “buy” rating in a report on Thursday, August 17th.
In related news, Director Venbio Select Advisor Llc purchased 1,150,000 shares of Immunomedics stock in a transaction dated Tuesday, November 14th. The stock was bought at an average cost of $10.39 per share, for a total transaction of $11,948,500.00. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, insider David M. Goldenberg sold 20,000 shares of Immunomedics stock in a transaction that occurred on Friday, September 1st. The shares were sold at an average price of $12.64, for a total transaction of $252,800.00. The disclosure for this sale can be found here. 6.60% of the stock is currently owned by company insiders.
Several hedge funds have recently bought and sold shares of the company. FMR LLC raised its position in shares of Immunomedics by 260.6% during the 2nd quarter. FMR LLC now owns 5,496,851 shares of the biopharmaceutical company’s stock worth $48,537,000 after purchasing an additional 3,972,388 shares during the last quarter. State Street Corp raised its position in shares of Immunomedics by 37.2% during the 2nd quarter. State Street Corp now owns 4,818,847 shares of the biopharmaceutical company’s stock worth $42,549,000 after purchasing an additional 1,305,298 shares during the last quarter. Vanguard Group Inc. raised its position in shares of Immunomedics by 2.4% during the 2nd quarter. Vanguard Group Inc. now owns 4,522,091 shares of the biopharmaceutical company’s stock worth $39,930,000 after purchasing an additional 105,558 shares during the last quarter. Farallon Capital Management LLC raised its position in shares of Immunomedics by 1.7% during the 2nd quarter. Farallon Capital Management LLC now owns 4,227,500 shares of the biopharmaceutical company’s stock worth $37,329,000 after purchasing an additional 72,500 shares during the last quarter. Finally, Palo Alto Investors LLC acquired a new position in shares of Immunomedics during the 2nd quarter worth approximately $26,582,000. Institutional investors own 62.61% of the company’s stock.
Shares of Immunomedics (IMMU) traded up $0.13 on Monday, reaching $11.15. The company’s stock had a trading volume of 912,200 shares, compared to its average volume of 3,077,106. Immunomedics has a 12 month low of $3.01 and a 12 month high of $14.48. The company has a debt-to-equity ratio of -0.29, a quick ratio of 0.74 and a current ratio of 0.74.
Immunomedics, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in developing monoclonal antibody-based products for the targeted treatment of cancer, autoimmune disorders and other serious diseases. Its geographic segments include United States and Europe. Its technologies allow it to create humanized antibodies that can be used either alone in unlabeled or naked form, or conjugated with radioactive isotopes, chemotherapeutics, cytokines or toxins.